Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $3.2 million.

  • Lifecore Biomedical, Inc. \De\'s Free Cash Flow fell 4586.04% to $3.2 million in Q2 2025 from the same period last year, while for May 2025 it was -$13.6 million, marking a year-over-year increase of 2490.35%. This contributed to the annual value of -$13.6 million for FY2025, which is 2490.35% up from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its Free Cash Flow stood at $3.2 million for Q2 2025, which was down 4586.04% from -$4.3 million recorded in Q1 2025.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Free Cash Flow peaked at $6.0 million during Q2 2024, and registered a low of -$23.3 million during Q1 2022.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Free Cash Flow had a median value of -$7.9 million in 2021 and averaged -$7.9 million.
  • As far as peak fluctuations go, Lifecore Biomedical, Inc. \De\'s Free Cash Flow plummeted by 65863.6% in 2021, and later surged by 16362.48% in 2024.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Free Cash Flow stood at -$10.2 million in 2021, then surged by 39.41% to -$6.2 million in 2022, then surged by 52.06% to -$3.0 million in 2023, then crashed by 188.6% to -$8.6 million in 2024, then skyrocketed by 137.88% to $3.2 million in 2025.
  • Its Free Cash Flow was $3.2 million in Q2 2025, compared to -$4.3 million in Q1 2025 and -$8.6 million in Q4 2024.